140 related articles for article (PubMed ID: 15797371)
1. Clinical outcome of long-term lamivudine treated chronic HBV infected and HIV/HBV coinfected patients.
Elefsiniotis IS; Paparizos V; Dourakis SP; Mpotsi C; Pantazis KD; Katsambas N
J Clin Virol; 2005 May; 33(1):80-2. PubMed ID: 15797371
[No Abstract] [Full Text] [Related]
2. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
3. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
4. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517
[TBL] [Abstract][Full Text] [Related]
5. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B in HIV co-infected patients.
Guan R
Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
[TBL] [Abstract][Full Text] [Related]
7. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
9. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
Bessesen M; Ives D; Condreay L; Lawrence S; Sherman KE
Clin Infect Dis; 1999 May; 28(5):1032-5. PubMed ID: 10452630
[TBL] [Abstract][Full Text] [Related]
10. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
[TBL] [Abstract][Full Text] [Related]
11. The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
Puoti M; Cozzi-Lepri A; Ancarani F; Bruno R; Ambu S; Ferraro T; Tundo P; Santantonio T; Toti M; Bonasso M; d'Arminio Monforte A; ;
Antivir Ther; 2004 Oct; 9(5):811-7. PubMed ID: 15535419
[TBL] [Abstract][Full Text] [Related]
12. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
[TBL] [Abstract][Full Text] [Related]
13. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
15. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
[TBL] [Abstract][Full Text] [Related]
16. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
17. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
[TBL] [Abstract][Full Text] [Related]
18. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
[TBL] [Abstract][Full Text] [Related]
19. Reversibility of cirrhosis in HIV/HBV coinfection.
Mallet VO; Dhalluin-Venier V; Verkarre V; Correas JM; Chaix ML; Viard JP; Pol S
Antivir Ther; 2007; 12(2):279-83. PubMed ID: 17503671
[TBL] [Abstract][Full Text] [Related]
20. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]